InDex Pharmaceuticals Holding AB (publ) year-end report 2020
Financing secured for phase III development of cobitolimod“With the equity financing secured until the next pivotal read-out of clinical data, it feels very inspiring to now advance cobitolimod into phase III, which is the final stage of development before application for market approval,” says Peter Zerhouni, CEO of InDex Pharmaceuticals. Period October – December 2020 · Net sales amounted to SEK 0.0 (0.0) million · Operating loss amounted to SEK –10.1 (–25.6) million · Result after tax amounted to SEK –10.1 (–25.6) million, corresponding to SEK –0.04 per share (–0.11) before